These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 14599111

  • 21. Paget's disease of bone: reduction of disease activity with oral risedronate.
    Hosking DJ, Eusebio RA, Chines AA.
    Bone; 1998 Jan; 22(1):51-5. PubMed ID: 9437513
    [Abstract] [Full Text] [Related]

  • 22. Bone scintigraphy in evaluation of Didronel therapy for Paget's disease.
    Lee JY.
    Clin Nucl Med; 1981 Aug; 6(8):356-8. PubMed ID: 6455232
    [Abstract] [Full Text] [Related]

  • 23. [Paget's disease: case report].
    Wegierska M, Ignaczak P, Zalewska J, Jeka S.
    Ann Acad Med Stetin; 2011 Aug; 57(3):64-9; discussion 69. PubMed ID: 23383549
    [Abstract] [Full Text] [Related]

  • 24. Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.
    Wimalawansa SJ, Gunasekera RD.
    Calcif Tissue Int; 1993 Oct; 53(4):237-41. PubMed ID: 8275351
    [Abstract] [Full Text] [Related]

  • 25. Beneficial effects of aminohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate.
    Delmas PD, Chapuy MC, Edouard C, Meunier PJ.
    Am J Med; 1987 Aug; 83(2):276-82. PubMed ID: 3113247
    [Abstract] [Full Text] [Related]

  • 26. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
    Alvarez L, Guañabens N, Peris P, Vidal S, Ros I, Monegal A, Bedini JL, Deulofeu R, Pons F, Muñoz-Gomez J, Ballesta AM.
    Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of scintigraphic and roentgenologic studies in Paget's disease under treatment.
    Vellenga CJ, Pauwels EK, Bijvoet OL, Hosking DJ.
    Radiol Clin (Basel); 1976 Nov; 45(2-4):292-301. PubMed ID: 821096
    [Abstract] [Full Text] [Related]

  • 28. Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone.
    Altman RD.
    Am J Med; 1985 Nov; 79(5):583-90. PubMed ID: 3933343
    [Abstract] [Full Text] [Related]

  • 29. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L, Peris P, Guañabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Muñoz-Gomez J, Ballesta AM.
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [Abstract] [Full Text] [Related]

  • 30. Active Paget's disease of bone with normal biomarkers of bone metabolism: a case report and review of the literature.
    Gkouva L, Andrikoula M, Kontogeorgakos V, Papachristou DJ, Tsatsoulis A.
    Clin Rheumatol; 2011 Jan; 30(1):139-44. PubMed ID: 20886248
    [Abstract] [Full Text] [Related]

  • 31. Effective short term treatment of Paget's disease with oral etidronate.
    Preston CJ, Yates AJ, Beneton MN, Russell RG, Gray RE, Smith R, Kanis JA.
    Br Med J (Clin Res Ed); 1986 Jan 11; 292(6513):79-80. PubMed ID: 3080099
    [Abstract] [Full Text] [Related]

  • 32. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR.
    J Bone Miner Res; 2007 Jan 11; 22(1):142-8. PubMed ID: 17032148
    [Abstract] [Full Text] [Related]

  • 33. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P, Alvarez L, Vidal S, Martínez MA, Monegal A, Guañabens N.
    Clin Exp Rheumatol; 2007 Jan 11; 25(2):206-10. PubMed ID: 17543143
    [Abstract] [Full Text] [Related]

  • 34. Skeletal scintimaging and radiography in the diagnosis and management of Paget's disease.
    Wellman HN, Schauwecker D, Robb JA, Khairi MR, Johnston CC.
    Clin Orthop Relat Res; 1977 Jan 11; (127):55-62. PubMed ID: 410575
    [Abstract] [Full Text] [Related]

  • 35. Successful treatment of resistant Paget's disease of bone with pamidronate.
    Mallette LE.
    Arch Intern Med; 1989 Dec 11; 149(12):2765-7. PubMed ID: 2596945
    [Abstract] [Full Text] [Related]

  • 36. Duration of effect of oral diphosphonate therapy in Paget's disease of bone.
    Gray RE, Yates AJ, Preston CJ, Smith R, Russell RG, Kanis JA.
    Q J Med; 1987 Sep 11; 64(245):755-67. PubMed ID: 2966965
    [Abstract] [Full Text] [Related]

  • 37. [Amino-hydroxy-propylidene biphosphonate in the treatment of Paget's disease resistant to calcitonin and/or etidronate].
    Miravet L, Kuntz D.
    Rev Rhum Mal Osteoartic; 1989 Mar 15; 56(4):287-92. PubMed ID: 2496460
    [Abstract] [Full Text] [Related]

  • 38. Treatment of Paget's Disease of Bone with Denosumab: Case Report and Literature Review.
    Reid IR, Sharma S, Kalluru R, Eagleton C.
    Calcif Tissue Int; 2016 Sep 15; 99(3):322-5. PubMed ID: 27193832
    [Abstract] [Full Text] [Related]

  • 39. Bisphosphonates for Paget's disease of bone in adults.
    Corral-Gudino L, Tan AJ, Del Pino-Montes J, Ralston SH.
    Cochrane Database Syst Rev; 2017 Dec 01; 12(12):CD004956. PubMed ID: 29192423
    [Abstract] [Full Text] [Related]

  • 40. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).
    Altman RD, Johnston CC, Khairi MR, Wellman H, Serafini AN, Sankey RR.
    N Engl J Med; 1973 Dec 27; 289(26):1379-84. PubMed ID: 4201876
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.